Streetbeat News

Products Services

AAPL

Apple Inc (NASDAQ:AAPL) is set to host a digital launch event on May 7, focusing on new developments in its iPad and iPhone lineups, with anticipated enhancements and a focus on AI at the WWDC in June. Amid a 12% stock decline in 2024, these launches are viewed as potential catalysts for a rebound, especially with AAPL's stock currently at a critical support level around $165, after fluctuating between $165 and $200 since July 2023.

Portfolio Pulse from Zaheer Anwari

April 29, 2024 | 2:03 pm

MRNA

MYNZ

PFE

mRNA technology, known for its role in COVID-19 vaccines by Pfizer and Moderna, is now promising breakthroughs in cancer diagnostics and treatment. Mainz Biomed reported significant findings from a clinical study on its ColoAlert® CRC screening test, showing high sensitivity and specificity rates. The study, involving 690 subjects across the U.S. and Europe, used novel mRNA biomarkers and a proprietary AI algorithm. Moderna, in partnership with OpenAI, is advancing mRNA medicine further by integrating AI technologies like a customized version of ChatGPT, mChat, into its operations.

Portfolio Pulse from Upwallstreet

April 29, 2024 | 2:02 pm

TSLA

Tesla Inc's Model 3 and Model Y have passed China's data security requirements, a crucial step for deploying its full self-driving (FSD) software in China. The China Association of Automobile Manufacturers confirmed the compliance of these models along with others from companies like BYD, Ideal, Lotus, Hezhong New Energy, and NIO. This development follows CEO Elon Musk's recent visit to China and a partnership with Baidu Inc for navigation data, indicating progress towards launching FSD in the Chinese market.

Portfolio Pulse from Anan Ashraf

April 29, 2024 | 2:02 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced positive Phase 2 trial data for Tacrolimus Inhalation Powder (TFF TAC) for lung transplant rejection prevention, presented at the ISHLT Annual Meeting. The data show TFF TAC prevents rejection with lower doses and systemic exposures than oral tacrolimus, and normalizes rejection-related gene expressions. The company plans to advance the program into potentially registrational testing.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:01 pm

AAPL

TSLA

Wedbush analyst Dan Ives highlighted Apple Inc. (AAPL) and Tesla Inc. (TSLA) as the only two companies successfully navigating the complex relationship between the U.S. and China, especially in the context of artificial intelligence and market challenges. Despite recent struggles in China, with Apple experiencing a 19% drop in iPhone sales and Tesla a 9% revenue decline, Ives remains optimistic about their prospects. He credits their success to superior product quality and strategic moves, such as Tesla's partnership with Baidu. Apple's shares rose 3.4%, and Tesla's surged 12.50% recently.

Portfolio Pulse from Rounak Jain

April 29, 2024 | 1:52 pm

KO

MSFT

NVDA

Microsoft Corporation (NASDAQ:MSFT) exceeded third-quarter earnings expectations with a 17% YoY revenue increase to $61.86 billion and net income of $21.94 billion. The company's Azure cloud and AI services saw significant growth, contributing to its commercial cloud revenue of $35.1 billion. Microsoft's investments in Nvidia Corporation (NASDAQ:NVDA) GPUs for AI development have led to a data center capacity challenge, mirroring Nvidia's own AI demand pressures. A new $1.1 billion agreement with The Coca-Cola Company (NYSE:KO) aims to accelerate AI transformation across Coca-Cola's global business. Despite strong performance, Microsoft anticipates near-term capacity constraints and plans a significant rise in capital expenditures for cloud infrastructure.

Portfolio Pulse from Upwallstreet

April 29, 2024 | 1:51 pm

ALB

Albemarle (NYSE:ALB) has seen unusual options activity, with a mix of bullish and bearish sentiments among high-rolling investors, as tracked by Benzinga. The activity includes 10 options trades, with a bullish sentiment in 50% of the trades. Significant investors are targeting a price range of $90.0 to $125.0 for ALB over the next three months. The company, a leading lithium producer for batteries, especially in electric vehicles, has its stock currently up by 4.95% at $122.67. Analyst ratings in the last month have been positive, with an average target price of $149.0.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 1:47 pm

IMMX

Immix Biopharma has been awarded the European Union Orphan Drug Designation for NXC-201, aimed at treating multiple myeloma. This designation grants NXC-201 ten years of market exclusivity in the EU, access to the EU centralized authorization procedure, and reduced fees for various regulatory and marketing processes.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:39 pm

JKS

JinkoSolar Holding Co Ltd (NYSE:JKS) reported Q1 fiscal 2024 results with a slight revenue miss but a strong outlook, leading to a share price rally. Revenue fell 1.2% Y/Y to $3.19 billion, below the $3.25 billion consensus. However, shipments surged 51.2% Y/Y to 21,907 MW. Gross margin decreased to 11.9% from 17.3% Y/Y, and the company reported a loss from operations. Despite this, adjusted net income was reported, and the company is optimistic about future demand, especially for N-type technology, with plans to limit capacity expansion to focus on advanced N-type capacity.

Portfolio Pulse from Akanksha Bakshi

April 29, 2024 | 1:32 pm

AZN

DSKYF

DSNKY

AstraZeneca reported positive results from a metastatic breast cancer treatment study for Enhertu, showing significant improvement in progression-free survival. Additionally, AstraZeneca's Truqap, in combination with Faslodex, is recommended for approval in the EU for certain breast cancer patients. Daiichi Sankyo, co-developer of Enhertu, also plays a role in these developments.

Portfolio Pulse from Vandana Singh

April 29, 2024 | 1:26 pm